Drugs / PRO-122
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03966365 | May → Aug 2019 | glaucoma | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03193333 | Nov 2017 → Oct 2024 | open-angle glaucoma | Laboratorios Sophia S.A de C.V. | Terminated | No outcome recorded |
| Phase 3 | NCT03257813 | Apr 2016 → Mar 2017 | ocular hypertension, open-angle glaucoma | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRO-122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03966365 ↗ |
| Route | Other | “Route of administration: ophthalmic” NCT03193333 ↗ |